Literature DB >> 10391849

CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses.

M Nakagawa1, D P Stites, J M Palefsky, Z Kneass, A B Moscicki.   

Abstract

Cytotoxic T-lymphocyte (CTL) responses to E6 and E7 were previously shown to be more commonly detectable in human papillomavirus type 16 (HPV-16)-positive women without squamous intraepithelial neoplasia (SIL) than in HPV-16-positive women with SIL (M. Nakagawa, D. P. Stites, S. Farhat, J. R. Sisler, B. Moss, F. Kong, A. B. Moscicki, and J. M. Palefsky, J. Infect. Dis. 175:927-931, 1997). The objective of this study was to characterize the phenotype(s) of the effector cell population responsible for HPV-16 E6- and E7-specific cytotoxic responses. Peripheral blood mononuclear cells were stimulated with HPV-16 E6 or E7 fusion protein. Cells from an autologous B-lymphoblastoid cell line, infected with vaccinia virus expressing E6 or E7, served as target cells. The effector cells were characterized by using natural-killer-cell removal, antibody blocking, and T-cell subset separation. Our results suggest that both CD4 and CD8 T lymphocytes contribute to HPV-16 E6- and E7-specific CTL responses although their relative contributions vary from individual to individual. On the other hand, natural killer cells in the effector cell population contribute to background activities but not to HPV-specific responses in this assay system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391849      PMCID: PMC95714          DOI: 10.1128/CDLI.6.4.494-498.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  17 in total

1.  Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein.

Authors:  B K Ab; R Kiessling; J D Van Embden; J E Thole; D S Kumararatne; P Pisa; A Wondimu; T H Ottenhoff
Journal:  Eur J Immunol       Date:  1990-02       Impact factor: 5.532

2.  Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages.

Authors:  L Rénia; D Grillot; M Marussig; G Corradin; F Miltgen; P H Lambert; D Mazier; G Del Giudice
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

3.  A virus-specific CD4+ cell-mediated cytolytic activity revealed by CD8+ cell elimination regularly develops in uncloned human antiviral cell lines.

Authors:  I Bourgault; A Gomez; E Gomard; F Picard; J P Levy; E Gomrad
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

4.  Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs.

Authors:  R Khanna; S R Burrows; S A Thomson; D J Moss; P Cresswell; L M Poulsen; L Cooper
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

5.  Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.

Authors:  E M Evans; S Man; A S Evans; L K Borysiewicz
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

6.  The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.

Authors:  A B Moscicki; S Shiboski; J Broering; K Powell; L Clayton; N Jay; T M Darragh; R Brescia; S Kanowitz; S B Miller; J Stone; E Hanson; J Palefsky
Journal:  J Pediatr       Date:  1998-02       Impact factor: 4.406

7.  Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation.

Authors:  D C Wraith; B A Askonas
Journal:  J Gen Virol       Date:  1985-06       Impact factor: 3.891

8.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

Authors:  M E Ressing; A Sette; R M Brandt; J Ruppert; P A Wentworth; M Hartman; C Oseroff; H M Grey; C J Melief; W M Kast
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

9.  Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.

Authors:  S A Hammond; R C Bollinger; P E Stanhope; T C Quinn; D Schwartz; M L Clements; R F Siliciano
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

10.  Specificity of cytotoxicity T cells directed to influenza virus hemagglutinin.

Authors:  T J Braciale
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Authors:  Dai-Wei Liu; Yuh-Cheng Yang; Ho-Fan Lin; Mei-Fang Lin; Ya-Wen Cheng; Chen-Chung Chu; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

3.  Development of chimeric candidate vaccine against HPV18: a proof of concept.

Authors:  Mohammed Wahiduzzaman; Chandresh Sharma; Bindu Dey; Neerja Bhatla; Neeta Singh
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

4.  Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response.

Authors:  Mark E Scott; Yifei Ma; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2014-10-30       Impact factor: 7.396

5.  Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.

Authors:  Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

6.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

Review 7.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

Review 8.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

9.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

10.  Investigating Human Papilloma Virus Types in Sinonasal Papilloma Using Polymerase Chain Reaction: Is It Really a Prerequisite for Nasal Papilloma Formation?

Authors:  Alireza Mohebbi; Mohammad Aghajanpour; Maryam Roomiani; Ali Zare-Mirzaie
Journal:  Maedica (Bucur)       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.